Anavar

[anabolichulk]

Oh course cardio and diet is the best way but she wants a little strength and yes anavar does help burn a little fat!

[Hazard]

Oh course cardio and diet is the best way but she wants a little strength and yes anavar does help burn a little fat!

How so exaclty? Do you have a study to show that? I'm just curious......

~Haz~

[kaigab]

How so exaclty? Do you have a study to show that? I'm just curious......

~Haz~

I know studies are on old people or sick people. Still Oxandrolone reduced fat in old people without exercise.

The effects of an anabolic agent on body composition and pulmonary function in tetraplegia: a pilot study.

Halstead LS, Groah SL, Libin A, Hamm LF, Priestley L.

National Rehabilitation Hospital, Research Division, Washington, DC, USA.

Study design:Prospective repeated-measures longitudinal study.Objectives:To determine if an 8-week course of an oral anabolic steroid can positively effect body composition or pulmonary function in healthy individuals with chronic tetraplegia.Setting:United States.Methods:Oxandrolone (20 mg per day) was administered for 8 weeks to 10 men with motor complete tetraplegia. Dual X-ray absorptiometry scans, pulmonary function tests (PFTs), serum lipids and liver function tests (LFTs) were obtained at baseline, 4, 8, 12 and 20 weeks. To analyze change over time, a repeated measures General Linear Model and nonparametric tests were utilized.Results:Following treatment, total lean body mass (LBM) increased 1.9% and LBM of the arms increased 5.4%. Total body fat decreased 1.5%, and increased 3.9% in the arms and, on average, combined measures of PFTs improved 2.2%. High-density lipoprotein cholesterol decreased 31.8%, low density lipoprotein cholesterol increased 41.2%, and LFTs increased 9.7-65.6% while on therapy but all trended to baseline at 20 weeks.Conclusion:Baseline body composition was characterized by a high proportion of fat and a body mass index that underestimated chronic disease risk. Treatment with oxandrolone was associated with modest improvements in PFTs and in arm and total body LBM. Unfavorable changes in serum lipids and LFTs indicate that reported benefits of using oxandrolone in this population must be carefully weighed against potential adverse effects.Spinal Cord advance online publication, 7 July 2009; doi:10.1038/sc.2009.82.

J Clin Endocrinol Metab. 2004 Oct;89(10):4863-72.
Effects of androgen therapy on adipose tissue and metabolism in older men.

Schroeder ET, Zheng L, Ong MD, Martinez C, Flores C, Stewart Y, Azen C, Sattler FR.

Department of Medicine and Division of Infectious Diseases, University of Southern California, Los Angeles, California 90033, USA.

We investigated the effects of oxandrolone on regional fat compartments and markers of metabolism. Thirty-two 60- to 87-yr-old men (body mass index, 28.1 +/- 3.4 kg/m(2)) were randomized to oxandrolone (20 mg/d; n = 20) or matching placebo (n = 12) treatment for 12 wk. Oxandrolone reduced total (-1.8 +/- 1.0 kg; P < 0.001), trunk (-1.2 +/- 0.6 kg; P < 0.001), and appendicular (-0.6 +/- 0.6 kg; P < 0.001) fat, as determined by dual energy x-ray absorptiometry. The changes in total and trunk fat were greater (P < 0.001) than the changes with placebo. By magnetic resonance imaging, visceral adipose tissue decreased (-20.9 +/- 12 cm(2); P < 0.001), abdominal sc adipose tissue (SAT) declined (-10.7 +/- 12.1 cm(2); P = 0.043), the ratio VAT/SAT declined from 0.57 +/- 0.23 to 0.49 +/- 0.19 (P = 0.002), and proximal and distal thigh SC fat declined [-8.3 +/- 6.7 cm(2) (P < 0.001) and -2.2 +/- 3.0 kg (P = 0.004), respectively]. Changes in proximal and distal thigh SC fat with oxandrolone were different than with placebo (P = 0.018 and P = 0.059). A marker of insulin sensitivity (quantitative insulin sensitivity check index) improved with oxandrolone by 0.0041 +/- 0.0071 (P = 0.018) at study wk 12. Changes in total fat, abdominal SAT, and proximal extremity SC fat were correlated with changes in fasting insulin from baseline to study wk 12 (r >or= 0.45; P < 0.05). Losses of total fat and SAT were greater in men with baseline testosterone of 10.4 nmol/liter or less (<or= 300 ng/dl) than in those with higher levels [-2.5 +/- 1.1 vs. -1.5 +/- 0.8 kg (P = 0.036) and -24.1 +/- 14.3 vs. -2.9 +/- 21.3 cm(2) (P = 0.03), respectively]. Twelve weeks after discontinuing oxandrolone, 83% of the reductions in total, trunk, and extremity fat by dual energy x-ray absorptiometry scanning were sustained (P < 0.02). Androgen therapy, therefore, produced significant and durable reductions in regional abdominal and peripheral adipose tissue that were associated with improvements in estimates of insulin sensitivity. However, high-density lipoprotein cholesterol decreased by -0.49 +/- 0.21 mmol/liter and directly measured low-density lipoprotein cholesterol increased by 0.57 +/- 0.67 mmol/liter and non-high-density lipoprotein cholesterol increased by 0.54 +/- 0.97 mmol/liter (P < 0.03 for each) during treatment with oxandrolone; these changes were largely reversible. Thus, therapy with an androgen that does not adversely affect lipids may be beneficial for some components of the metabolic syndrome in overweight older men with low testosterone levels.

[Hazard]

I know studies are on old people or sick people. Still Oxandrolone reduced fat in old people without exercise.

The effects of an anabolic agent on body composition and pulmonary function in tetraplegia: a pilot study.

Halstead LS, Groah SL, Libin A, Hamm LF, Priestley L.

National Rehabilitation Hospital, Research Division, Washington, DC, USA.

Study design:Prospective repeated-measures longitudinal study.Objectives:To determine if an 8-week course of an oral anabolic steroid can positively effect body composition or pulmonary function in healthy individuals with chronic tetraplegia.Setting:United States.Methods:Oxandrolone (20 mg per day) was administered for 8 weeks to 10 men with motor complete tetraplegia. Dual X-ray absorptiometry scans, pulmonary function tests (PFTs), serum lipids and liver function tests (LFTs) were obtained at baseline, 4, 8, 12 and 20 weeks. To analyze change over time, a repeated measures General Linear Model and nonparametric tests were utilized.Results:Following treatment, total lean body mass (LBM) increased 1.9% and LBM of the arms increased 5.4%. Total body fat decreased 1.5%, and increased 3.9% in the arms and, on average, combined measures of PFTs improved 2.2%. High-density lipoprotein cholesterol decreased 31.8%, low density lipoprotein cholesterol increased 41.2%, and LFTs increased 9.7-65.6% while on therapy but all trended to baseline at 20 weeks.Conclusion:Baseline body composition was characterized by a high proportion of fat and a body mass index that underestimated chronic disease risk. Treatment with oxandrolone was associated with modest improvements in PFTs and in arm and total body LBM. Unfavorable changes in serum lipids and LFTs indicate that reported benefits of using oxandrolone in this population must be carefully weighed against potential adverse effects.Spinal Cord advance online publication, 7 July 2009; doi:10.1038/sc.2009.82.

J Clin Endocrinol Metab. 2004 Oct;89(10):4863-72.
Effects of androgen therapy on adipose tissue and metabolism in older men.

Schroeder ET, Zheng L, Ong MD, Martinez C, Flores C, Stewart Y, Azen C, Sattler FR.

Department of Medicine and Division of Infectious Diseases, University of Southern California, Los Angeles, California 90033, USA.

We investigated the effects of oxandrolone on regional fat compartments and markers of metabolism. Thirty-two 60- to 87-yr-old men (body mass index, 28.1 +/- 3.4 kg/m(2)) were randomized to oxandrolone (20 mg/d; n = 20) or matching placebo (n = 12) treatment for 12 wk. Oxandrolone reduced total (-1.8 +/- 1.0 kg; P < 0.001), trunk (-1.2 +/- 0.6 kg; P < 0.001), and appendicular (-0.6 +/- 0.6 kg; P < 0.001) fat, as determined by dual energy x-ray absorptiometry. The changes in total and trunk fat were greater (P < 0.001) than the changes with placebo. By magnetic resonance imaging, visceral adipose tissue decreased (-20.9 +/- 12 cm(2); P < 0.001), abdominal sc adipose tissue (SAT) declined (-10.7 +/- 12.1 cm(2); P = 0.043), the ratio VAT/SAT declined from 0.57 +/- 0.23 to 0.49 +/- 0.19 (P = 0.002), and proximal and distal thigh SC fat declined [-8.3 +/- 6.7 cm(2) (P < 0.001) and -2.2 +/- 3.0 kg (P = 0.004), respectively]. Changes in proximal and distal thigh SC fat with oxandrolone were different than with placebo (P = 0.018 and P = 0.059). A marker of insulin sensitivity (quantitative insulin sensitivity check index) improved with oxandrolone by 0.0041 +/- 0.0071 (P = 0.018) at study wk 12. Changes in total fat, abdominal SAT, and proximal extremity SC fat were correlated with changes in fasting insulin from baseline to study wk 12 (r >or= 0.45; P < 0.05). Losses of total fat and SAT were greater in men with baseline testosterone of 10.4 nmol/liter or less (<or= 300 ng/dl) than in those with higher levels [-2.5 +/- 1.1 vs. -1.5 +/- 0.8 kg (P = 0.036) and -24.1 +/- 14.3 vs. -2.9 +/- 21.3 cm(2) (P = 0.03), respectively]. Twelve weeks after discontinuing oxandrolone, 83% of the reductions in total, trunk, and extremity fat by dual energy x-ray absorptiometry scanning were sustained (P < 0.02). Androgen therapy, therefore, produced significant and durable reductions in regional abdominal and peripheral adipose tissue that were associated with improvements in estimates of insulin sensitivity. However, high-density lipoprotein cholesterol decreased by -0.49 +/- 0.21 mmol/liter and directly measured low-density lipoprotein cholesterol increased by 0.57 +/- 0.67 mmol/liter and non-high-density lipoprotein cholesterol increased by 0.54 +/- 0.97 mmol/liter (P < 0.03 for each) during treatment with oxandrolone; these changes were largely reversible. Thus, therapy with an androgen that does not adversely affect lipids may be beneficial for some components of the metabolic syndrome in overweight older men with low testosterone levels.

The problem with overweight older men is their testosterone is already low..... depending on age/weight/genetics it could be severely low. I firmly DO NOT believe anavar will help a healthy younger individual lose fat. If they are taking anavar..... and doing cardio..... i'm willing to bet it's the cardio that does it. If not.... then a diet change.

I'll open my eyes to anavar burning fat when someone from here takes it without working out and doesn't change their diet. If their bodyfat visibly reduces..... i'll be convinced.

~Haz~

[BJJ]

How so exaclty? Do you have a study to show that? I'm just curious......

~Haz~

http://forums.steroid.com/showthread.php?t=403234

It did on my body.

[elpropiotorvic]

http://forums.steroid.com/showthread.php?t=403234

It did on my body.

I thought you gained body fat?

[BJJ]

I thought you gained body fat?

Yes I did because I was not trying to get ripped but to test the ability of Oxandrolone to develop lean mass.
However, the last two weeks I reduced the daily calories and noticed a double percentage reduction of fat compared to lean mass.

[Hazard]

Yes I did because I was not trying to get ripped but to test the ability of Oxandrolone to develop lean mass.
However, the last two weeks I reduced the daily calories and noticed a double percentage reduction of fat compared to lean mass.

Thats with a caloric drop tho..... if you hadn't lowered calories..... would bodyfat have still dropped?

If you were taking var and you gained some BF while trying to test the lean mass gains then that sort of debunks the "var will cut fat" myth IMO.

~Haz~

[BJJ]

Thats with a caloric drop tho..... if you hadn't lowered calories..... would bodyfat have still dropped?

If you were taking var and you gained some BF while trying to test the lean mass gains then that sort of debunks the "var will cut fat" myth IMO.

~Haz~

I disagree.
I reached almost 6000 Kcal daily while testing var and for two consecutive weeks I ate more than 4000 Kcal daily.
There is a limit for every drug and I guess with var and my organism, the limit is not to go over 1500 Kcal daily.
I mean I was eating 4000 but burning throughout the day 2500. See what I mean?

In any case, I speak with numbers on hand, numbers took by my own experience. 8 Weeks of var and almost 12 lbs of lean mass and no much fat difference.
Actually, to say it all, when I took the BMC prior the cycle I was leaner than when I started it more than two weeks after. So, I was not anymore 12,7% bf but much closer to 14% bf, like I am now.
I weight now almost 97kg and I am quicker than before (bjj) when I was less than 90kg! NO WATER, NO FAT.

So, Oxandrolone showd ME, it has burning fat capabilities.

You wanted a study on this with your specific requests, be my guest:
http://www.anabolicsteroids.co.za/pr...45-oxandrolone